Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself
At present GLP-1 mimics, including semaglutide, are available for some groups on the NHS, although prescriptions can only be given for a maximum of two years because of a lack of long-term data
an omega-6 fatty acid) the two core fatty acids found in gray matter
Lets learn about key hormones and their roles: Thyroid hormones (T3 and T4): set the metabolic pace Insulin : controls glucose entry into cells Cortisol : chronic stress elevates cortisol levels, leading to increased blood sugar and fat storage Leptin and Ghrelin: regulate hunger and fullness
Several biological and behavioral factors influence how the body responds to GLP-1 medications: 1
Amit Rajguru is a board-certified internal medicine specialist who has helped many patients enhance their quality of life with minimally invasive treatments
